论文部分内容阅读
上皮样胶质母细胞瘤(E-GBMs)的BRAF V600E突变率可高达50%以上,而普通型GBMs突变率很低,提示E-GBMs最可能为GBMs的一种变异亚型。BRAF基因状态检测是决定靶向药物vemurafenib使用的重要依据。采用BRAF VE1免疫组化(IHC)检测是否可以替代Sanger测序目前尚不清楚。作者早期研究显示E-GBMs患者BRAF VE1 IHC与
The mutation rate of BRAF V600E in epithelioid glioblastoma (E-GBMs) can be up to 50%, while the mutation rate of common GBMs is very low, suggesting that E-GBMs are most likely to be a variant of GBMs. BRAF gene status test is to determine the use of targeted drugs vemurafenib important basis. It is not yet clear whether BRAF VE1 immunohistochemistry (IHC) can replace Sanger sequencing. An earlier study by the authors showed that E-GBMs BRAF VE1 IHC and